Physician profile
Amanda Whitten
NPI 1568248474
$2,143.78
in general payments reported to CMS, 2019-2025
23 companies · $786 in 2025
The $786 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $660 · 2024: $698 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,143.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $300.45 | 2024-2025 | Farxiga |
| Lilly USA, LLC | $221.67 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $199.63 | 2024-2025 | Ozempic, Rybelsus, Saxenda |
| Sk Life Science, INC. | $174.32 | 2023-2024 | |
| Pfizer INC. | $162.48 | 2023-2025 | |
| Abbvie INC. | $154.40 | 2025 | |
| Glaxosmithkline, LLC. | $131.12 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Neurelis, INC. | $110.29 | 2023 | Valtoco |
| Ucb, INC. | $101.02 | 2023 | Nayzilam |
| Shield Therapeutics INC | $84.81 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $77.14 | 2023-2024 | Austedo Xr, Ajovy |
| Alexion Pharmaceuticals, INC. | $63.28 | 2023 | Ultomiris |
| Phathom Pharmaceuticals, INC. | $63.18 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.28 | 2024-2025 | Xifaxan, Trulance |
| Amneal Pharmaceuticals LLC | $41.24 | 2023 | Rytary |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $41.06 | 2023 | Vumerity |
| Otsuka America Pharmaceutical, INC. | $39.99 | 2023-2024 | Rexulti, Nuedexta |
| Genentech USA, INC. | $39.11 | 2023 | Enspryng, Ocrevus |
| Dexcom, INC. | $36.75 | 2024-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $18.01 | 2024 | |
| Merck Sharp & Dohme LLC | $17.93 | 2024 | Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.90 | 2025 | Jardiance |
| Corium, LLC | $7.72 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Whitten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.